ARTICLE | Clinical News
Tenofovir alafenamide fumarate: Additional Phase III data
May 2, 2016 7:00 AM UTC
Additional secondary endpoint data from the double-blind, international Phase III Study 108 in 425 hepatitis B e antigen (HBeAg)-negative chronic HBV-infected patients showed that once-daily 25 mg ora...